Chemiluminescence Immunoassay Based Serological Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Vaccinated Population
Open Access
Abstract
The development of rapid serological detection methods re urgently needed for determination of neutralizing antibodies in sera. In this study, four rapid methods (ACE2-RBD inhibition assay, S1-IgG detection, RBD-IgG detection, and N-IgG detection) were established and evaluated based on chemiluminescence technology. For the first time, a broadly neutralizing antibody with high affinity was used as a standard for the quantitative detection of SARS-CoV-2 specific neutralizing antibodies in human sera. Sera from COVID-19 convalescent patients (N = 119), vaccinated donors (N = 86), and healthy donors (N = 299) confirmed by microneutralization test (MNT) were used to evaluate the above methods. The result showed that the ACE2-RBD inhibition assay calculated with either ACE2-RBD binding inhibition percentage rate or ACE2-RBD inhibiting antibody concentration were strongly correlated with MNT (r ≥ 0.78, p < 0.0001) and also highly consistent with MNT (Kappa Value ≥ 0.94, p < 0.01). There was also a strong correlation between the two evaluation indices (r ≥ 0.99, p < 0.0001). Meanwhile, S1-IgG and RBD-IgG quantitative detection were also significantly correlated with MNT (r ≥ 0.73, p < 0.0001), and both methods were highly correlated with each other (r ≥ 0.95, p < 0.0001). However, the concentration of N-IgG antibodies showed a lower correlation with the MNT results (r < 0.49, p < 0.0001). The diagnostic assays presented here could be used for the evaluation of SARS-CoV-2 vaccine immunization effect and serological diagnosis of COVID-19 patients, and could also have guiding significance for establishing other rapid serological methods to surrogate neutralization tests for SARS-CoV-2.Keywords
Funding Information
- National Science and Technology Major Project ((2018ZX10711-001)(2017YFA0205100))
This publication has 32 references indexed in Scilit:
- Neutralizing Antibodies against SARS-CoV-2 and Other Human CoronavirusesTrends in Immunology, 2020
- COVID-19: Epidemiology, Evolution, and Cross-Disciplinary PerspectivesTrends in Molecular Medicine, 2020
- Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptorCellular & Molecular Immunology, 2020
- Structural and functional analysis of a potent sarbecovirus neutralizing antibodybioRxiv, 2020
- Structural basis for human coronavirus attachment to sialic acid receptorsNature Structural & Molecular Biology, 2019
- Chemiluminescent immunoassay technology: what does it change in autoantibody detection?Autoimmunity Highlights, 2017
- Antibody Detection: Principles and Applications2012
- Evaluation of a new serological technique for detecting rabies virus antibodies following vaccinationVaccine, 2012
- Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra virusesExpert Opinion on Biological Therapy, 2009
- Homogeneous immunoassay based on chemiluminescence energy transfer.Clinical Chemistry, 1983